EMA acts to impose some sort of order on secondary data analysis
This article was originally published in Scrip
The European Medicines Agency concedes it will not be able to police all secondary data analyses undertaken by independent researchers once it grants them access to raw clinical trial data submitted in support of EU drug applications.
You may also be interested in...
Five new drugs have been recommended for EU approval at the latest meeting of European Medicines Agency’s drug evaluation committee.
The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.